Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New knee implant tested for Long-Term success

NCT ID NCT02380092

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study follows 163 people who received a LEGION knee replacement with a special VERILAST bearing surface to treat degenerative joint disease. Researchers track how long the implant lasts and how well patients function over time. The goal is to see if this newer device performs as well as or better than an older model.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LEGION Primary Total Knee System with VERILAST bearing surface (a knee replacement device)
What this could lead to
If successful, this could confirm that the LEGION knee system is a safe and durable option for people needing knee replacement due to arthritis.
What could go wrong
This is a post-market study, not a new treatment. Results may not show major improvement over existing options, and some patients may still need revision surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

163 people

The number who actually took part.

Started

Sep 2015

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects who are scheduled to have Total Knee Arthroplasty with the Legion Primary Total Knee System due to Degenerative Joint Disease.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject requires primary TKA and has elected to use the LEGION™ Primary TKS with VERILAST™. * Subject requires primary TKA due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis). * Subject is of legal age to consent, agrees to consent to and to follow the study visit schedule (as defined in the study protocol and informed consent form), by signing the EC approved informed consent form. * Routine radiographic assessment is possible. * Subject plans to be available through ten (10) years postoperative follow-up. * Subject is 18-75 years of age at the time of surgery. Exclusion Criteria: * Age \> 75 years at the time of surgery. * Subjects with immunosuppressive disorders. * Subject has severe pronation of the ipsilateral foot or any other relevant clinical condition contributing to abnormal ambulation (including but not limited to ankle fusion, ankle arthroplasty, previous hip fracture, ipsilateral hip arthritis resulting in flexion contracture). * Subject has undergone a previous major surgery to the study knee (including osteotomy, fracture fix, medial or lateral ligament surgery). * Subject has active infection or sepsis (treated or untreated). * At the time of enrollment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator: * Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty. * Contralateral primary total knee or unicondylar knee arthroplasty. * Subject has presence of malignant tumor, metastatic, or neoplastic disease. * Subject has conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease). * Subject has any acute or chronic morbidity of vascular origin that, in the opinion of the Investigator, is likely to compromise successful treatment or compliance to follow-up visits. * Subject has inadequate bone stock to support the device (severe osteopenia, family history of severe osteoporosis or osteopenia). * Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study. * Subject has a Body Mass Index (BMI) \>40.0. * Subject requires revision TKA. * Subject is expected to require bilateral TKA within 1 year following study knee replacement. * Subject does not understand the language used in the Informed Consent Form. * Subject is enrolled in another clinical study at the same time.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative joint disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AMEOS Klinikum Seepark Geestland

    Langen, Kreis Geestland, 27607, Germany

  • CaritasKlinikum St. Joseph Saarbrücken-Dudweiler

    Saarbrücken-Dudweiler, 66125, Germany

  • Evangelisches Krankenhaus Wien

    Vienna, 1180, Austria

  • KniePraxis Prof. Dr. Tibesku

    Straubing, 94315, Germany

  • OrthoCentrum

    Hamburg, 20149, Germany

  • Orthopadische Krankenhaus Gersthof

    Vienna, 1180, Austria

  • Servicio de C.O.T. Hospital Clínico Universitario de Santiago de Compostela

    Santiago de Compostela, 15706, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.